Total Complement Hemolytic Activity (CH50) Assay: 50% Hemolysis Testing – Principles, Methods, and A

The Total Complement Hemolytic Activity assay, widely known as the CH50 or 50% hemolysis test, is a functional laboratory method that quantifies the overall activity of the classical complement pathway in serum. This article provides a comprehensive technical overview of CH50 testing, covering its underlying principle, sample requirements, analytical procedures, clinical and industrial applications, and answers to frequently asked questions.

Technical Overview

The complement system consists of more than 30 soluble and membrane-bound proteins that mediate opsonization, inflammatory signaling, and complement-dependent cytotoxicity through three activation routes: the classical pathway, the lectin pathway, and the alternative pathway. The CH50 assay (50% hemolytic unit of complement) provides a global functional readout of the classical pathway, because lysis of antibody-sensitized erythrocytes requires every classical component to be present and biologically active, namely C1q, C1r, C1s, C4, C2, C3, C5, C6, C7, C8, and C9.

In the assay, sheep red blood cells (SRBC) coated with rabbit anti-sheep erythrocyte antibody (hemolysin) form immune complexes that bind C1q and trigger the classical cascade. Sequential activation culminates in assembly of the membrane attack complex (C5b-9), which perforates the erythrocyte membrane and causes osmotic lysis. The hemoglobin released into the supernatant is measured by absorbance at 540–541 nm and is directly proportional to the functional complement activity of the specimen.

The relationship between serum concentration and percentage of hemolysis follows a sigmoidal curve described by the von Krogh equation. The curve reaches its steepest slope at 50% hemolysis, where small changes in complement concentration produce the largest measurable change in lysis; this is why the assay endpoint is deliberately fixed at the 50% hemolysis point, maximizing analytical sensitivity and precision. One CH50 unit is defined as the quantity of complement present in a stated volume of serum that lyses 50% of a standardized suspension of sensitized erythrocytes under defined reaction conditions, and results are typically reported in U/mL or as a percentage of a pooled normal reference serum. In healthy adults, reference intervals commonly fall in the range of approximately 30–60 U/mL, although each laboratory must verify its own method-specific interval.

Testing Samples

Human Serum

Venous blood should be collected into a plain serum tube or serum separator tube. Anticoagulants such as EDTA, citrate, or oxalate are unsuitable because they chelate the calcium and magnesium ions that are essential for complement activation. After clotting for 30–60 minutes at room temperature, the sample is centrifuged and serum is separated promptly, ideally within two hours of collection.

• Short-term storage: 2–8 °C and tested the same day whenever possible.
• Long-term storage: frozen at −70 °C or below in single-use aliquots to avoid repeated freeze–thaw cycles.
• Never heat-inactivate the sample (56 °C for 30 minutes destroys complement activity).
• Reject grossly hemolyzed, severely lipemic, or microbially contaminated specimens, as free hemoglobin and turbidity interfere with the spectrophotometric reading at 541 nm.

Animal Serum for Preclinical and Research Studies

Serum from mice, rats, guinea pigs, rabbits, and non-human primates is frequently analyzed in immunopharmacology and immunotoxicology programs. Because susceptibility of erythrocyte targets and reagent compatibility vary by species, method feasibility must be verified for each animal model. Specimens should be snap-frozen on dry ice and stored at −80 °C to preserve labile complement components.

Biological Extracts and Medical Device Contact Matrices

For hemocompatibility evaluation of blood-contacting medical devices, human serum or anticoagulated blood exposed to test materials under controlled incubation conditions can be analyzed for residual CH50 activity and complement activation markers, supporting assessment of complement consumption by biomaterials.

Testing Items

The core deliverable of this test is the quantitative determination of total complement hemolytic activity (CH50) reflecting classical pathway function. In comprehensive complement workups performed by accredited third-party laboratories and clinical immunology laboratories, CH50 is typically bundled with the following related analytes:

• AH50: alternative pathway hemolytic activity, usually measured with rabbit or guinea pig erythrocytes.
• Individual complement proteins: C3, C4, C1q, C2, factor B, factor D, properdin, and mannose-binding lectin (MBL).
• Complement activation split products: C3a, C5a, iC3b, Bb, C4d, and the soluble terminal complex SC5b-9.

Interpretation follows a defined algorithm: a low CH50 with low C3 and low C4 indicates classical pathway activation, as seen in immune complex disease; low C3 with normal C4 and normal CH50 suggests alternative pathway activation; and an absent CH50 points toward a homozygous deficiency of a single classical component requiring reflex component-level testing.

Testing Methods

Classical Tube Hemolytic Assay (Mayer Method)

The reference manual procedure is performed in isotonic veronal-buffered saline supplemented with calcium chloride, magnesium chloride, and gelatin or albumin (VBS++), at pH 7.3–7.4. Washed sheep erythrocytes are standardized photometrically to a fixed cell concentration (for example 5 × 10⁸ cells per mL) and sensitized with an optimally titrated dilution of rabbit hemolysin to produce EA cells. Serial dilutions of the test serum and a pooled reference serum are prepared, mixed with the EA cell suspension, and incubated at 37 °C for 30–60 minutes with gentle agitation. After centrifugation, the absorbance of each supernatant is read at 541 nm against the cell blank and the 100% hemolysis control (cells lysed in distilled water). The percentage of lysis is transformed according to the von Krogh equation, plotted against serum dilution, and the dilution producing 50% hemolysis is interpolated. The CH50 value equals the reciprocal of that dilution multiplied by the initial dilution factor, reported as U/mL.

Microplate Spectrophotometric Method

The classical procedure has been miniaturized to 96-well format with automated plate readers and multichannel pipetting. A calibration curve generated with a pooled normal serum calibrator permits calculation of CH50 directly from the lysis curve, improving throughput, reducing reagent consumption, and enabling standardized batch analysis in hospital and contract research laboratories.

Automated Liposome-Based Complement Assay

Modern analyzer platforms use liposomes encapsulating glucose-6-phosphate dehydrogenase and displaying hapten groups on their surface. Antibody-directed classical pathway activation assembles the membrane attack complex on the liposome membrane, releasing the enzyme, whose activity is quantified colorimetrically. This homogeneous approach eliminates donor erythrocytes, shortens turnaround time, and offers reproducible results suitable for routine clinical screening.

Quality Control and Standardization

• Calibrate against an in-house pooled normal serum or an accepted biological reference preparation and verify lot-to-lot consistency of erythrocytes and hemolysin.
• Confirm erythrocyte concentration, hemolysin optimum dilution, incubation temperature, and timing before each analytical run.
• Run normal and abnormal control sera with each batch and monitor performance using Levey–Jennings charts with predefined acceptance limits.
• Validate precision, linearity, limit of detection, and reference intervals in accordance with CLSI method evaluation guidance.

Applications

Clinical Immunology and Disease Monitoring

• Screening for hereditary complement deficiencies in patients with recurrent pyogenic infections or invasive Neisserial disease; an undetectable CH50 triggers reflex testing of individual components.
• Serial monitoring of systemic lupus erythematosus activity, where falling CH50 alongside rising anti-dsDNA antibodies and falling C3/C4 precedes or confirms nephritic flares.
• Evaluation of immune complex and complement-mediated disorders, including post-streptococcal glomerulonephritis, membranoproliferative glomerulonephritis, cryoglobulinemia, and mixed connective tissue disease.
• Assessment of acquired hypocomplementemia in sepsis, burns, pancreatitis, cirrhosis, liver failure, and severe malnutrition.

Medical Device Biocompatibility Evaluation

Under ISO 10993-4, blood-contacting devices such as hemodialyzers, oxygenators, catheters, and stents are evaluated for complement activation. CH50 measurement, together with C3a, C5a, and SC5b-9 quantification, demonstrates whether a biomaterial consumes or activates complement under simulated clinical contact conditions, supporting regulatory submissions and material selection studies.

Drug Development and Bioanalysis

CH50 serves as a pharmacodynamic marker for complement-targeted therapeutics, including anti-C5 monoclonal antibodies and small-molecule inhibitors, and supports immunogenicity assessments where drug-induced immune complexes may consume complement. The assay is also applied in vaccine adjuvant research and in the functional characterization of biosimilar biotechnology products.

FAQ

Why is the endpoint set at 50% hemolysis rather than 100%?

The dose–response curve of complement-mediated lysis is sigmoidal and steepest at the 50% point. At this region, a minimal change in complement concentration produces the largest measurable change in hemolysis, giving the assay its highest precision and sensitivity, as described by the von Krogh equation.

What does a low CH50 result mean?

A reduced or absent CH50 indicates either classical pathway consumption due to immune complex disease, glomerulonephritis, sepsis, or cryoglobulinemia; decreased hepatic synthesis in liver failure; or a hereditary deficiency of a single classical pathway component. Because the assay requires all classical components, even one missing factor abolishes detectable activity.

How does CH50 differ from C3 and C4 immunoassays?

CH50 measures the functional capacity of the entire classical cascade, whereas C3 and C4 immunoassays quantify the antigenic concentration of individual proteins. A patient can have normal concentrations but dysfunctional activity, or near-normal antigen levels with marked consumption, so the two approaches are complementary.

Can the assay be performed on plasma?

No. Standard CH50 testing requires serum, because common anticoagulants chelate calcium and magnesium ions that are indispensable for complement activation and would falsely depress the result.

How should samples be handled to preserve complement activity?

Serum must be separated quickly, kept at 2–8 °C for same-day testing, or frozen at −70 °C or below in aliquots. Repeated freeze–thaw cycles, delayed processing, hemolysis, and heat inactivation all degrade complement and must be avoided.

What is the difference between CH50 and AH50?

CH50 evaluates the classical pathway using antibody-sensitized sheep erythrocytes, while AH50 evaluates the alternative pathway using unsensitized rabbit or guinea pig erythrocytes. Comparing the two results localizes a deficiency to the early classical components, the shared terminal components, or the alternative pathway.

What is a typical turnaround time?

Manual and microplate hemolytic assays are usually completed within one working day once a suitable specimen is received; automated liposome-based platforms can return results within hours. Reflex component testing, when required, may extend the reporting timeline.

Which industries rely on CH50 testing?

Clinical diagnostic laboratories, medical device manufacturers conducting ISO 10993-4 hemocompatibility studies, pharmaceutical companies developing complement-modulating therapies, and contract research organizations all routinely use CH50 testing to evaluate complement system status.